Novartis to acquire Avidity Biosciences for $12 billion
ReutersOct 26, 2025 5:05 PM
Oct 26 (Reuters) - Swiss drugmaker Novartis NOVN.S on Sunday said it agreed to acquire Avidity Biosciences for $12 billion.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Tesla’s Megapack Leads the Surge in Energy Storage Stocks
TradingKey - Long an afterthought in the U.S. energy system, grid-scale battery storage is rapidly moving from the margins to the mainstream.TradingKey
Fri, Oct 24
Thinking of investing in SOL? Here's a deep dive into Solana’s price trends and future outlook
Solana has demonstrated strong technical resilience and ecosystem growth in 2025. If it continues expanding use cases, stabilizing network performance, and navigating regulatory hurdles, SOL could become a core Web3 infrastructure asset. Institutions remain bullish on its long-term potential, especiTradingKey
Fri, Oct 24
Intel Q3 Earnings Preview: Surge in Partnerships and Investments — Should You Bet Against a Turnaround?
TradingKey - Semiconductor chip manufacturer Intel (INTC) will report its Q3 2025 earnings after market close on Thursday, October 23, with investors watching closely to see if the company can finally prove it’s on a credible path to profitability. This quarter could mark a turning point, driven byTradingKey
Thu, Oct 23
Can Zcash (ZEC) Sustain Its Rally? What’s Next for Its Price Trajectory?
Launched in 2016, Zcash (ZEC) is a cryptocurrency focused on privacy protection. Its key innovation lies in selective privacy, allowing users to choose between transparent and shielded transactions.TradingKey
Sat, Oct 18
The Ultimate AI Investment Guide: Opportunities, Risks, and Strategies for the Next Generation of Technology Markets
TradingKey - OpenAI’s recent multi-billion-dollar partnerships—with Nvidia, AMD, and Broadcom—have flooded headlines and lifted markets, but they’ve also sparked a new round of debate: Is Sam Altman steering us toward a runaway tech bubbleTradingKey
Tue, Oct 14
